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Purpose: To investigate actual intraprostatic location of higher graded tumor foci undetected via standard transrectal ultrasound-
guided prostate biopsy amongst patients who would be clinically considered appropriate candidates for active surveillance (AS) but 
underwent radical prostatectomy (RP). 
Methods: We reviewed entirely-submitted and whole-mounted RP specimens from 169 men who were deemed appropriate for AS 
clinically, but opted for RP and were found to have higher grade tumors. For each case, tumor nodules were circled and color-coded 
in a grade-specific manner and digitally scanned to created tumor maps. The locations of tumor foci with Gleason grade ≥4 were 
stratified by specific sites: anterior, anterolateral, lateral only (not clearly anterior or posterior), posterior, and posterolateral area. 
Results: Of 169 patients, 86% had clinical stage T1c and 14% T2a. RP Gleason score 7 in all but two men. Higher-grade tumor foci 
were localized to: anterior (n =66, 39%), anterolateral (n =4, 2%), lateral only (not clearly anterior or posterior) (n =5, 3%), posterior 
(n=52, 31%), and posterolateral (n=42, 25%) prostate, respectively.
Conclusions: Among patients deemed clinically appropriate for AS, higher-grade tumor foci missed by standard prostate biopsies 
were localized to both the anterior and posterior prostate, without predominance of a particular area. These findings lend additional 
support to performing repeat standard prostate biopsy in potential candidates for AS and should be considered in efforts to optimize 
current biopsy strategies for the selection of AS patients.
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INTRODUCTION
Accurate identification of insignificant and/or low-risk pros-
tate cancer (PCa) is crucial for the success of active surveil-
lance (AS) in the current era of prostate specific antigen (PSA) 
screening. Various predictive nomograms have been devel-
oped to aid the selection of patients for AS [1-4]. However, in-
ability of current staging modalities to discriminate aggressive 
from indolent PCa with optimal sensitivity and specificity, 
mostly conferred by inaccuracy of current standard transrec-
tal ultrasound (TRUS)–guided schematic biopsy approach, 
remains a significant drawback. Although most smaller tumor 
foci missed by contemporary 12-core TRUS–guided biopsy 
may be clinically irrelevant, published data suggest that some 
of these patients may actually harbor significant tumor of 
higher grade [5,6]. Similarly, the therapeutic efficacy and safe-
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ty of novel focal therapies for unilateral PCa has been ques-
tioned based upon apparent inaccuracy of prostate biopsy [7]. 
 Some reports have suggested that tumor foci in the anterior 
and/or apical prostate are those primarily missed by standard 
schematic prostate biopsy, advocating additional sampling 
of the corresponding areas during prostate biopsy [8,9]. How-
ever, patients included in prior studies were not limited to 
those who would qualify for AS. In an effort to improve ac-
curacy in the selection of patients for AS, investigators have 
explored changes in prostate biopsy approaches, including 
implementation of saturation biopsy and/or using transperi-
neal approach [10,11]. More definitive evidence is needed to 
justify such alternative approaches in prostate biopsy, at least 
for potential AS candidates, since they would be prone to in-
crease biopsy-related morbidity and cost. 
 In order to develop a biopsy approach or protocol that 
would enhance accuracy in the selection of patients for AS, 
it is plausible to begin by examining the actual intraprostatic 
locations of tumor foci of higher grade missed amongst po-
tential candidates for AS. Currently, a paucity of data exists re-
garding the localization and characterization of higher graded 
tumor foci undetected via standard TRUS–guided prostate 
biopsy amongst patients who would be clinically considered 
appropriate candidates for AS. Thus, we performed detailed 
histopathologic analysis of patients who were candidates for 
AS clinically, but opted for immediate radical prostatectomy 
(RP) and were found to have higher grade tumors.
MATERIALS AND METHODS
From January 2000 to December 2010, a total of 7,016 patients 
underwent RP for clinically localized PCa at Memorial Sloan-
Kettering Cancer Center (MSKCC). With approval from the 
Institutional Review Board, we reviewed our prospectively 
collected multidisciplinary PCa database to select patients 
who were deemed appropriate for AS clinically, but instead, 
opted for RP and were found to have higher grade tumors. 
Inclusion criteria included: preoperative PSA, < 10 ng/mL; 
clinical stage, T1c–T2a; biopsy Gleason score (GS), 6; ≤ 3 posi-
tive cores on at least 12-core prostate biopsy; and no core with 
> 50% cancer. For this study, only those who were not en-
rolled on AS prior to RP were included. Overall a total of 1,690 
patients met aforementioned inclusion criteria. Among these 
1,690 men, 682 had GS upgrading following RP. And of the 
682, 169 men who had all the clinical variables and tumor map 
obtained from analyzing RP specimen available were included 
in our study. None of 169 patients had undergone preoperative 
radiation or hormonal therapy.
 In all patients, RP specimens were entirely-submitted and 
whole-mounted for pathologic analysis. RP specimens were 
uniformly processed as previously reported [12,13]. After di-
agnosis, all cases were mapped with differential annotation of 
Gleason grade < 3 and > 4 and then digitally scanned. Review 
of whole-mount tumor maps to detect locations of high grade 
tumor foci was performed by a dedicated urologic pathologist 
(S.W.F) were identified. A topography–based approach was 
applied and the location of tumor foci with Gleason grade ≥4 
were stratified by site, as follows: anterior, anterolateral, lateral 
only (not clearly anterior or posterior), posterior, and postero-
lateral area. The presence of extraprostatic extension, seminal 
vesicle invasion, positive surgical margin and/or lymph node 
involvement was also recorded.
 Clinical data of patients were obtained from the review of 
our database and medical records. Descriptive statistics were 
utilized to characterize the subjects. Chi-square tests and t-
tests were used to describe categorical and continuous vari-
ables, respectively. All analyses were conducted using STATA 
12.0 (StataCorp LP., College Station, TX, USA).
RESULTS
Table 1 summarizes the characteristics of the 169 patients. 
In this cohort, median age was 63.2 years (mean, 64.1 years; 
range, 48 to 74 years), and median PSA was 5.4 ng/mL (mean, 
5.6 ng/mL; range, 0.47 to 5.51 ng/mL). Overall median pros-
tate volume was 36.5 mL (mean, 40.5 mL; range, 5 to 120 mL). 
Among these 169 patients, clinical stage was T1c in 145 (86%) 
and T2a in 24 (14%).
 Analysis of RP specimens revealed pathological GS of 7 in 
99% of men. Extraprostatic extension and positive surgical 
margins were observed in 30 (18%) and 23 of patients (14%), 
respectively. Seminal vesicle invasion and lymph node in-
volvement were not observed in any patient. 
 Tumor map analysis revealed that tumor foci with Gleason 
grade ≥ 4 were anterior in 66 (39%), anterolateral in 4 (2%), 
lateral (not clearly anterior or posterior) in 5 (3%), posterior in 
52 (31%), and posterolateral in 42 (25%). There was no signifi-
cant difference in the percentage of higher-graded tumor foci 
located in the anterior and posterior prostate (P = 0.764). 
DISCUSSION
For more than two decades, TRUS–guided biopsy has been 
the standard method of detecting PCa. Although there is no 
consensus among experts as to which biopsy strategy is op-
timal, it is now widely accepted that initial prostate biopsy 
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should include at least 10 to 12 cores [14]. Even with that stan-
dard, a false-negative biopsy rate up to 30% for initial TRUS–
guided biopsies and up to 50% for repeat biopsies has been 
reported. Sampling error is an inherent feature of any biopsy 
approach and is compounded by the difficulty in accessing 
certain regions of the prostate using the transrectal approach. 
As treatment approaches such as AS and focal therapy gain 
more attention, the diagnostic accuracy of prostate biopsy 
has been further challenged. 
 Several groups have compared the pathologic findings from 
prostate needle biopsy and RP in potential candidates for AS. 
In a retrospective analysis of 366 European men who received 
RP for clinically insignificant PCa, Jeldres et al. [6] reported 
that 8.3% had non–organ-confined disease on RP and 24% 
actually had cancer of higher ( ≥ 7) GS. A retrospective study 
reviewing outcomes after RP in 398 potential AS candidates 
from the SEARCH database revealed GS upgrading in 36%, 
extraprostatic extension in 16% and seminal vesicle invasion 
in 2% [15]. Similarly, a recent European multicenter study on 
919 patients, who fulfilled relatively more stringent selection 
criteria for AS (PSA, ≤ 10 ng/mL; clinical stage, T1c; GS, < 7; 
and a single positive core with tumor length, < 3 mm), found 
GS upgrading in 34% and only 26% of patients with pathologi-
cally insignificant cancer [16]. Finally, among 626 patients en-
rolled in Prostate Cancer Research International: Active Sur-
veillance (PRIAS) study who underwent immediate RP, GS 
upgrading was present in 44.9% [17]. Although the selection 
criteria for AS differ by institutions, this collective data clearly 
demonstrates that a single session of TRUS–guided biopsy 
offers limited accuracy in revealing tumor aggressiveness in 
potential candidates for AS.
 A number of investigators have examined the ability of 
contemporary extended prostate biopsy to predict the exact 
location of tumor in RP specimens. From observing low nega-
tive predictive values for right (24.7%) and left (31.3%) biopsy 
in predicting tumor laterality, Schulte et al. [18] concluded 
that standard 12-core biopsies failed to provide reliable local-
ization of tumors to specific areas of the prostate. They found 
no useful preoperative predictors for predicting pathologic 
agreement between biopsy and RP specimens for patients 
with low-risk PCa. Furthermore, Iremashvili et al. [19] ana-
lyzed the diagnostic performance of individual biopsy local-
ization and found that lateral cores from the mid and base 
prostate along with apical cores showed lower diagnostic ac-
curacies for detecting tumor foci than other cores in patients 
who all had systematic 12-core TRUS–guided prostate biopsy. 
Focusing on patients with unilaterally negative preoperative 
biopsy, Bolenz et al. [20] observed that dorsolateral regions, 
followed by anterior apical area were the most frequent loca-
tions of tumor foci undetected by biopsy in RP specimens. 
 Meanwhile, a paucity of data exists on the actual locations 
of tumor foci with higher Gleason grade undetected by con-
temporary prostate biopsy schemes amongst the potential 
candidates for AS. From analyzing RP specimens of 66 pa-
tients who met selection criteria (PSA < 10 ng/mL and only 
one positive core showing either GS 3+3 of < 3.0 mm or 3+4 
of < 2.0 mm) for AS, Davis et al. [21] found that tumor foci of 
transition zone origin contributed to a significant number of 
cases of an underestimated tumor volume. In a study of 51 
patients with early stage PCa who were on AS and later un-
Table 1. Patient characteristics
Characteristic Value
Age at RP (yr)
Mean (median) 64.1 (63.2)
SD 6.6
RP type
Open 84 (49.7)
Robotic 16 (9.5)
Pure laparoscopic 69 (40.8)
PSA (ng/mL)
Mean (median) 5.6 (5.4)
SD 2.0
TRUS volume
Mean (median) 40.5 (36.5)
SD 15.9
Clinical stage
T1c 145 (85.8)
T2a 24 (14.2)
Biopsy Gleason score
<6 0 (0)
6 169 (100)
No. positive cores
1 83 (49.1)
2 61 (36.1)
3 25 (14.8)
No. total biopsy cores
12 133 (78.7)
≥13 36 (21.3)
Maximum % core involvement with cancer
Mean (median) 14.1 (10.0)
SD 11.7
Pathologic Gleason score
7 167 (98.8)
≥8 2 (1.2)
Extracapsular extension 30 (17.8)
Seminal vesicle invasion 0 (0)
Positive surgical margin 23 (13.6)
Values are presented as number (%) unless otherwise indicated.
RP, radical prostatectomy; SD, standard deviation; PSA, prostate specific 
antigen; TRUS, transrectal ultrasound.
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derwent RP, Washington et al. [22] reported that biopsy cor-
rectly identified the sextant with the highest grade in only 37% 
of RP specimens and that identification of dominant grade 
did not differ significantly by location in the prostate ( < 50% 
accuracy for apex, mid, and base, respectively). Neither study 
offers additional analysis on the actual locations of higher-
graded tumor foci undetected by initial biopsy in patients 
with upgrading. Importantly, pathologic examination in these 
two studies was not performed using whole-mounted speci-
mens. In the current study of patients who were candidates 
for AS clinically, but opted for immediate RP and were found 
to have higher grade tumors, we observed that tumor foci with 
Gleason grade ≥4 were localized to both the anterior and pos-
terior prostate, without predominance of a particular area. 
 In an attempt to increase the accuracy of prostate biopsy 
in predicting GS preoperatively some have opted for a trans-
perineal saturation biopsy approach. Hossack et al. [23] com-
pared RP histopathologic findings of patients who received 
both transperineal and transrectal biopsy as the modality used 
to identify the initial cancer and found that transperineal bi-
opsy detected proportionally more anterior tumors (16.2% vs. 
12%) and identified them at smaller size (1.4 cm3 vs. 2.1 cm3) 
and stage (extraprostatic extension 13% vs. 28%) than tran-
srectal biopsy. A computer simulation study evaluating dif-
ferent prostate biopsy strategies found that standard 12-core 
TRUS biopsy performs poorly for detecting clinically signifi-
cant PCa compared to template mapping biopsies (TMB) in 
which median of 48 cores were obtained via transperineal ap-
proach [10]. They suggested that only marginal improvement 
can be achieved by adding anterior cores to TRUS biopsy and 
that the performance attained by TMB would be optimal. 
However, others have reported on the increased prevalence 
of tumors in the apex, suggesting the need for additional 
sampling of apical area during the prostate biopsy [24,25]. In 
a prospective trial in which all patients underwent a standard 
12-core biopsy plus 2 additional cores taken from anterior 
apex, Moussa et al. [26] observed that additional apical cores 
achieved the highest rate of unique cancer detection and 
increased overall cancer detection because of the preponder-
ance of PCa at this site. 
 Overall, our findings do not advocate additional sampling 
of a particular area only. Results of the current study can be in-
terpreted as providing support to performing repeat standard 
extended TRUS biopsy in potential candidates for AS. Ber-
glund et al. [27] found that immediate repeat biopsy in cases 
of AS with selective delayed intervention resulted in 27% be-
ing upgraded or up staged and those were more likely to show 
higher grade and stage disease at RP. From their findings, they 
recommended performing repeat biopsy in potential candi-
dates for AS. Barzell et al. [28] recently compared repeat TRUS 
biopsy with transperineal TMB in ruling out clinically signifi-
cant cancer in men with presumed favorable risk PCa being 
considered for AS. They found that repeat TRUS biopsy failed 
to detect up to 80% of clinically significant cancers detected 
by TMB and identified the anterior apex as the area most 
commonly missed by repeat TRUS biopsy. From such find-
ings, they suggested that TMB would outperform TRUS biop-
sy regardless of number of TRUS biopsy cores obtained since 
TRUS biopsy would miss many anterior tumors. However, the 
actual locations of tumors were verified by pathologic evalu-
ation of RP specimens in less than 15% of subjects in their 
study. Moreover, others have disputed the advantage of TMB 
over standard TRUS biopsy regimens citing cost-related and 
procedural issues [29]. 
 Although a nonnegligible proportion of clinically insignifi-
cant PCa continues to be reclassified as significant disease 
after RP as aforementioned, a question remains as to whether 
such upgrading is clinically important. To date, prospective 
AS series have provided satisfactory clinical outcomes despite 
the clear risks of upgrading and/or upstaging [30]. Additional 
long-term follow-up is clearly needed to determine whether 
there is a difference between pathologic and disease outcome 
in such group of patients. 
 The current may be limited by the following factors: 1) only 
patients who opted for curative surgery were included, possi-
bly eliciting selection bias; 2) the exact reason for proceeding 
to surgery could not be specified in all cases; 3) biopsies in 
many of our subjects were performed outside the institution 
(although all were reviewed at our institution). We did not 
analyze the locations of missed lesion with largest tumor vol-
ume, as the GS is a more dominant prognostic factor than tu-
mor volume regarding PCa. Additionally, the threshold tumor 
volume used to define clinically significant cancer remains 
open to debate. 
 In conclusion, among PCa patients deemed clinically ap-
propriate for AS, higher grade tumor foci missed by standard 
prostate biopsies were localized to both the anterior and pos-
terior prostate, without predominance of a particular area. 
These findings lend support to performing repeat standard 
prostate biopsy in potential candidates for AS and should be 
considered in efforts to optimize current biopsy strategies for 
the selection of AS patients.
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